Fig. 5. (A) Schematic illustration of the AMC release assay. (B) Peptides used for the AMC release assay. (C) AMC release efficiency of peptides 16–19 (5 μm) treated with caspase-3 protein for 1 h and monitored at 5 minute intervals. (D) Time-dependent release of AMC of peptides 16–19 (5 μm) treated with U2OS cell lysates in the absence and presence of caspase inhibitor FMK (100 μm) for 24 h. (E) Confocal microscopy images of U2OS cells after treatment with peptides 17i, 18i and 19 at 100 μM for 4 h, followed by incubation with GSH at 10 mM for 8, 16, or 24 h and then treatment with the apoptotic inducer ABT-737 (10 μM) for 1 h.
